Cullinan Therapeutics (CGEM) Insider Allen Buys 21,781 Shares

Andrew Allen acquired 21,781 shares of Cullinan Therapeutics, Inc. (CGEM) on June 16, 2026, according to recent regulatory filings. This acquisition was part of a broader cluster of insider activity at the biotechnology company, where several individuals picked up shares on the same date.

Insider Buying and Selling at Cullinan Therapeutics, Inc.

The move by Andrew Allen follows similar transactions by other key figures at the company. On June 16, 2026, David Meek and Mary Thistle both acquired 25,319 shares, while Mittie Doyle picked up 21,781 shares. These transactions appear to be awards or acquisitions where the reported price per share was $0.00, often seen with stock grants or restricted units. None of these transactions were conducted under a Rule 10b5-1 plan, which is a pre-scheduled trading plan used by insiders to avoid accusations of trading on private information.

Cullinan Therapeutics Stock Performance

Shares of Cullinan Therapeutics were trading at $14.44 on Thursday. The stock has experienced significant volatility over the past year, trading between a 52-week low of $5.68 and a high of $23.19. Currently, the stock is trading slightly below its 50-day moving average of $19.70 and just under its 200-day moving average of $15.15. With a market capitalization of roughly $1.31 billion, the company maintains a high current ratio of 8.42, which suggests it has a significant amount of cash or short-term assets relative to its immediate bills.

Analysts Set New Price Targets

Wall Street firms have remained positive on Cullinan Therapeutics throughout the late summer and early fall. On October 2, 2026, H.C. Wainwright & Co. reiterated its Buy rating with a $35.00 price target. This followed a September 25 move by BTIG to maintain a Buy rating while setting a $40.00 price target. Wedbush recently raised its target to $42.00 on August 13, 2026. The consensus among 11 analysts is currently a "strong buy," with a mean price target of $33.55, which is well above the current trading price.

About Cullinan Therapeutics

Cullinan Therapeutics is a biotechnology company based in Cambridge, Massachusetts, that focuses on developing treatments for autoimmune diseases and various forms of cancer. The company recently changed its name from Cullinan Oncology to reflect a broader focus on therapeutic areas beyond just cancer. Its pipeline includes several bispecific T cell engagers currently in Phase 1 clinical trials, aimed at treating conditions like acute myeloid leukemia and systemic lupus erythematosus.

What's Ahead for Cullinan Therapeutics, Inc.

Investors will likely watch for the company's next earnings report, which is expected on November 14, 2026. As a clinical-stage biotech firm, Cullinan Therapeutics is not yet profitable and does not pay a dividend, meaning its stock price is largely driven by clinical trial progress and regulatory updates. While insider buys can sometimes suggest internal confidence, these filings are backward-looking and may not reflect the insiders' current views on the stock's value.